RLAY Relay Therapeutics

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats:

  • TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. ET
  • Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 at 11:00 a.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: . An archived replay of the webcast will be available for up to 30 days following the event.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or .

Contact:

Pete Rahmer

Media:

Dan Budwick

1AB

973-271-6085



EN
24/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relay Therapeutics

 PRESS RELEASE

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial...

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates  Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer Presented interim data for RLY-2608 + fulvestrant showing 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Continued progression of other front-line breast cancer regimens, including initiation of atirmociclib triplet, and planning for development of future oral endocrine the...

 PRESS RELEASE

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. ETBarclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 at 11:00 a.m. ET The fireside chats will be webcast...

 PRESS RELEASE

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Finan...

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 30, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 23, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch